VHT vs. PJP: Which Healthcare ETF Is Better Positioned for 2026 Amid Sector Rally?

As the healthcare sector experiences a robust rally, investors seeking exposure through exchange-traded funds (ETFs) are evaluating options like the Vanguard Health Care ETF (VHT) and the Invesco Pharmaceuticals ETF (PJP). These two funds offer different approaches to healthcare investing, catering to various investor objectives. VHT provides broad exposure across the entire healthcare spectrum, whereas PJP maintains a more concentrated focus solely on pharmaceutical companies.

The Vanguard Health Care ETF (VHT) stands as one of the largest healthcare sector funds with $20.4 billion in assets under management (AUM), holding stocks of 411 companies within the healthcare industry. The fund aims to track the MSCI US Investable Market Health Care 25/50 Index, offering broad diversification across medical product providers, service companies, technology firms, and equipment manufacturers. VHT features a remarkably low expense ratio of 0.09% and an attractive dividend yield of 1.60%. In contrast, the Invesco Pharmaceuticals ETF (PJP) has a more modest AUM of $435.5 million and is concentrated in just 30 U.S. pharmaceutical companies, tracking the Dynamic Pharmaceutical Intellidex Index. PJP's expense ratio is higher at 0.57% compared to VHT, and its dividend yield is 0.90%. Over the past year (as of July 20, 2026), PJP recorded a 45.10% return, while VHT posted a 25.20% return. However, over a five-year period, PJP outperformed VHT, with a $1,000 investment growing to $1,540, compared to $1,281 for VHT.

The broader healthcare and pharmaceutical sector outlook for 2026 is characterized by significant growth opportunities alongside potential challenges. The pharmaceutical industry is projected to grow by 5.8% in 2026, driven by factors such as biologics, GLP-1 therapies, AI-driven drug discovery, and increasing global healthcare expenditure. However, the sector also faces headwinds from pricing reforms, looming patent expirations, and geopolitical uncertainties. The broader healthcare sector, while experiencing ongoing challenges like margin pressures, workforce shortages, and cybersecurity threats, maintains cautious optimism. Technological innovations and artificial intelligence are pivotal in driving operational efficiencies and advancements in diagnostics, supporting the sector's transformation.

In light of these developments, investors face a strategic choice between broad sector diversification and a more focused niche. VHT, with its comprehensive coverage of the entire healthcare sector, tends to offer lower volatility and the potential to benefit from growth across various healthcare sub-industries. Major players like Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV) hold significant weight in both funds, underscoring the impact of industry giants. PJP, by concentrating solely on pharmaceutical companies, may offer more direct leverage to rapid advancements in biologics and next-generation therapies, though this comes with a higher concentration of risk.

Analysts and market expectations suggest that merger and acquisition (M&A) activity in the pharmaceutical sector will continue robustly in 2026. Companies are expected to pursue strategic acquisitions to fill pipelines ahead of high-revenue drug patent expirations and strengthen their positions in next-generation therapies. In the broader healthcare sector, investments in AI-powered platforms are seen as a primary driver for growth, particularly in medical technology and diagnostics. Consequently, ETFs like VHT and PJP offer investors avenues to capitalize on these sector dynamics, with their scope and cost structures playing a decisive role in investment decisions.